Ask AI
ProCE Banner Activity

Overcoming Clinical Challenges in Integrating Avutometinib/Defactinib Into Routine Practice for KRAS-Mutated Low-Grade Serous Ovarian Carcinoma

Clinical Thought

This expert commentary highlights key clinical considerations for integrating avutometinib/defactinib into routine care for patients with KRAS-mutated low-grade serous ovarian carcinoma, focusing on practical challenges related to biomarker testing, treatment sequencing in an evolving therapeutic landscape, and long-term toxicity management to support durable disease control.

Released: February 24, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Verastem, Inc.

Verastem, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who manage patients with ovarian cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate biomarker testing into clinical practice to guide treatment of targeted agents in patients with KRAS-mutated low-grade serous ovarian cancer

  • Align clinical practice with recent key data and approvals supporting the use of dual MEK/FAK targeting in patients with KRAS-mutated low-grade serous ovarian cancer

  • Manage adverse events associated with MEK/FAK-targeted agents in patients with low-grade serous ovarian cancer

Disclosure

Primary Author

Rachel Grisham, MD: consultant/advisor/speaker: AstraZeneca, GSK, Incyclix, Incyte, SpringWorks; other financial or material support: Verastem.

Kathleen N. Moore, MD, MS, FASCO: consultant/advisor/speaker: Aadi, AbbVie, AstraZeneca, BeOne, BioNTech, Corcept, Daiichi Sankyo, Duality, Eisai, GSK, Immunogen, Iovance, Janssen, Merck, Regeneron, Schrödinger, Takeda, Verastem, Whitehawk, Zentalis, Zymeworks.